Status:
ACTIVE_NOT_RECRUITING
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Lead Sponsor:
Target PharmaSolutions, Inc.
Conditions:
Inflammatory Bowel Diseases
Crohn's Disease
Eligibility:
All Genders
2+ years
Brief Summary
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD wi...
Eligibility Criteria
Inclusion
- Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial.
- Have plans for future visits at the site for continued management of IBD.
Exclusion
- Inability to provide written informed consent/assent.
- Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).
- Prior total abdominal colectomy for UC or IBDU.
Key Trial Info
Start Date :
July 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT03251118
Start Date
July 24 2017
End Date
February 1 2026
Last Update
November 21 2025
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Om Research
Lancaster, California, United States, 93534
2
FACEY Medical Foundation
Mission Hills, California, United States, 91345
3
University of California - Davis
Sacramento, California, United States, 95817
4
Stanford University
Stanford, California, United States, 94305